Agilent Technologies, Inc. (NYSE:A) Shares Sold by Park Place Capital Corp

Park Place Capital Corp lowered its stake in shares of Agilent Technologies, Inc. (NYSE:A) by 46.8% during the first quarter, HoldingsChannel.com reports. The institutional investor owned 395 shares of the medical research company’s stock after selling 348 shares during the period. Park Place Capital Corp’s holdings in Agilent Technologies were worth $57,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in A. Livelsberger Financial Advisory purchased a new stake in Agilent Technologies in the 4th quarter valued at approximately $26,000. MV Capital Management Inc. boosted its stake in shares of Agilent Technologies by 120.7% during the 4th quarter. MV Capital Management Inc. now owns 192 shares of the medical research company’s stock worth $27,000 after acquiring an additional 105 shares in the last quarter. VisionPoint Advisory Group LLC purchased a new stake in shares of Agilent Technologies during the 4th quarter worth approximately $29,000. Rise Advisors LLC boosted its stake in shares of Agilent Technologies by 527.8% during the 1st quarter. Rise Advisors LLC now owns 226 shares of the medical research company’s stock worth $33,000 after acquiring an additional 190 shares in the last quarter. Finally, Baystate Wealth Management LLC boosted its stake in shares of Agilent Technologies by 107.3% during the 4th quarter. Baystate Wealth Management LLC now owns 257 shares of the medical research company’s stock worth $36,000 after acquiring an additional 133 shares in the last quarter.

Agilent Technologies Trading Down 1.7 %

A stock opened at $127.46 on Tuesday. Agilent Technologies, Inc. has a 52 week low of $96.80 and a 52 week high of $155.35. The company has a market cap of $37.19 billion, a price-to-earnings ratio of 30.13, a PEG ratio of 4.40 and a beta of 1.05. The company has a quick ratio of 1.64, a current ratio of 2.15 and a debt-to-equity ratio of 0.34. The business has a fifty day simple moving average of $139.56 and a 200-day simple moving average of $138.50.

Agilent Technologies (NYSE:A) last announced its quarterly earnings results on Wednesday, May 29th. The medical research company reported $1.22 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.19 by $0.03. Agilent Technologies had a return on equity of 26.25% and a net margin of 18.84%. The firm had revenue of $1.57 billion during the quarter, compared to the consensus estimate of $1.58 billion. During the same period in the prior year, the firm earned $1.27 EPS. The firm’s quarterly revenue was down 8.4% compared to the same quarter last year. On average, equities research analysts expect that Agilent Technologies, Inc. will post 5.25 EPS for the current year.

Agilent Technologies Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, July 24th. Stockholders of record on Tuesday, July 2nd will be paid a dividend of $0.236 per share. The ex-dividend date is Tuesday, July 2nd. This represents a $0.94 annualized dividend and a dividend yield of 0.74%. Agilent Technologies’s dividend payout ratio is presently 22.22%.

Insider Activity

In related news, CEO Padraig Mcdonnell sold 1,958 shares of Agilent Technologies stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $130.00, for a total value of $254,540.00. Following the completion of the transaction, the chief executive officer now directly owns 25,185 shares in the company, valued at $3,274,050. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, CEO Padraig Mcdonnell sold 1,958 shares of Agilent Technologies stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $130.00, for a total value of $254,540.00. Following the completion of the transaction, the chief executive officer now directly owns 25,185 shares in the company, valued at $3,274,050. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Dominique Grau sold 15,000 shares of the firm’s stock in a transaction dated Monday, June 10th. The stock was sold at an average price of $133.28, for a total transaction of $1,999,200.00. Following the completion of the transaction, the senior vice president now directly owns 49,486 shares in the company, valued at approximately $6,595,494.08. The disclosure for this sale can be found here.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on A shares. Stifel Nicolaus decreased their price target on Agilent Technologies from $163.00 to $151.00 and set a “buy” rating on the stock in a research note on Thursday, May 30th. TD Cowen decreased their price target on Agilent Technologies from $163.00 to $153.00 and set a “buy” rating on the stock in a research note on Thursday, May 30th. Robert W. Baird cut their price objective on Agilent Technologies from $147.00 to $136.00 and set an “outperform” rating for the company in a research report on Thursday, May 30th. Evercore ISI cut their price objective on Agilent Technologies from $145.00 to $126.00 and set an “in-line” rating for the company in a research report on Thursday, May 30th. Finally, Jefferies Financial Group reiterated a “hold” rating and issued a $135.00 price target (down from $152.00) on shares of Agilent Technologies in a report on Monday, June 3rd. One analyst has rated the stock with a sell rating, seven have given a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat, Agilent Technologies has an average rating of “Hold” and a consensus price target of $136.88.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.